Gerresheimer's Creditor Reprieve Sparks Rally, But Core Challenges Remain
Published on 04/16/2026 at 15:33 | Redaktion boerse-global.de
A double dose of news from Gerresheimer sent its shares soaring 18 percent in a single session, offering a rare moment of relief for a stock down nearly 59 percent over the past year. The German pharmaceutical packaging group announced two critical moves late Tuesday: creditors have granted a significant waiver on key debt covenants, and the sale process for its profitable US subsidiary, Centor Inc., is officially underway. While the market cheered, both developments come with strict deadlines and unresolved risks that continue to cloud the company's future.
The covenant waiver, approved by 96 percent of noteholders, suspends key financial maintenance tests related to leverage until the end of the third quarter of 2026. This applies to a total debt volume of 870 million euros and provides crucial breathing room, sharply reducing the near-term risk of a refinancing crunch. Concurrently, the company is pushing forward with the divestment of Centor, its US unit for prescription drug packaging systems. Managed by Morgan Stanley, the process has attracted a double-digit number of potential buyers, with Gerresheimer aiming to close a deal within this year.
This asset sale is a strategic necessity, not a choice. With a book value of 292 million euros at the end of 2024, Centor is considered the group's most profitable asset. Its sale is intended to stabilize Gerresheimer's overstretched capital structure. The company's conditional forecast for 2026, which projects revenue of 2.3 to 2.4 billion euros and an adjusted EBITDA margin of 18 to 19 percent, remains heavily dependent on the successful conclusion of bank talks and the resolution of ongoing regulatory issues.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Those regulatory pressures are mounting. Germany's financial watchdog, BaFin, has expanded its investigation to include leasing liabilities of approximately 65.5 million euros and capitalized development costs of 29.4 million euros. The delay in publishing audited accounts stems from internal investigations into 2024 and 2025 business transactions. An independent law firm identified that revenue from so-called bill-and-hold agreements was systematically recognized too early—a clear violation of IFRS rules.
The financial and governance crisis has already exacted a heavy toll. Since the start of the year, the share price has fallen roughly 36 percent, and it is down 65 percent over a twelve-month period. On April 10, 2026, STOXX formally removed Gerresheimer from the SDAX index after the company missed a four-month deadline for submitting its annual report. The company also faces non-cash impairments of 220 to 240 million euros, primarily related to technology projects at Sensile Medical AG and assets of Gerresheimer Moulded Glass Chicago Inc.
Management is now racing against a self-imposed deadline to regain credibility. While creditors extended the formal deadline for the audited 2025 annual report to September 30, 2026, Gerresheimer has committed to delivering it by June. The half-year report is scheduled for July 14, 2026. These dates, alongside the conclusion of the Centor sale, represent the next concrete checkpoints for investors to assess whether the restructuring is gaining real traction.
With the stock at 20.84 euros—34 percent above its 52-week low but still almost 68 percent below its high—the path forward remains fraught. The price-to-earnings ratio for 2026 stands at 6.48, which appears optically cheap but reflects the substantial uncertainties. For now, the creditor reprieve has staved off immediate disaster, but Gerresheimer's recovery hinges on executing a complex asset sale and finally delivering clean, audited financials to a skeptical market.
Ad
Gerresheimer Stock: New Analysis - 16 April
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
